Compare IGA & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGA | ACHV |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.7M | 172.0M |
| IPO Year | N/A | 2018 |
| Metric | IGA | ACHV |
|---|---|---|
| Price | $9.66 | $4.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 61.3K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.21 | $2.00 |
| 52 Week High | $10.12 | $6.03 |
| Indicator | IGA | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 55.60 |
| Support Level | $9.39 | $4.06 |
| Resistance Level | $9.67 | $5.13 |
| Average True Range (ATR) | 0.13 | 0.42 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 55.87 | 50.91 |
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.